A5025681025- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Advanced Neuroimaging Techniques and Applications
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Epilepsy research and treatment
- Functional Brain Connectivity Studies
- S100 Proteins and Annexins
- Medical Imaging Techniques and Applications
- Neurological Disease Mechanisms and Treatments
- Parkinson's Disease Mechanisms and Treatments
- Neuroscience and Neuropharmacology Research
- Neuroinflammation and Neurodegeneration Mechanisms
- Traumatic Brain Injury and Neurovascular Disturbances
- Diet and metabolism studies
- Down syndrome and intellectual disability research
- Folate and B Vitamins Research
- Neurological Disorders and Treatments
- Traumatic Brain Injury Research
- Bipolar Disorder and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Prion Diseases and Protein Misfolding
- Frailty in Older Adults
- Memory and Neural Mechanisms
- Pancreatic function and diabetes
- Lanthanide and Transition Metal Complexes
University of Gothenburg
2017-2025
Sahlgrenska University Hospital
2020-2025
Hospital Universitario Virgen del Rocío
2021
Instituto de Biomedicina de Sevilla
2021
Universidad de Sevilla
2021
Turku PET Centre
2021
University of Turku
2021
Neuroscience Institute
2021
University College London
2021
UK Dementia Research Institute
2021
Abstract The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or plasma, has shown great promise detecting Alzheimer’s disease (AD) pathophysiology. Tau at threonine 231 (p-tau231) is one such biomarker CSF but its usefulness as a blood currently unknown. Here, we developed an ultrasensitive Single molecule array (Simoa) for the plasma p-tau231 which was validated four independent cohorts ( n = 588) different settings, including full AD continuum and non-AD...
Article10 November 2020Open Access Transparent process Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of preclinical Alzheimer's continuum when only subtle changes Aβ pathology are detected Marc Suárez-Calvet orcid.org/0000-0002-2993-569X Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain IMIM (Hospital del Mar Medical Institute), Servei de Neurologia, Hospital Mar, Centro Investigación Biomédica en Red sFragilidad...
Glycine N-methyltransferase (GNMT) is the main enzyme responsible for catabolism of excess hepatic S-adenosylmethionine (SAMe). GNMT absent in hepatocellular carcinoma (HCC), messenger RNA (mRNA) levels are significantly lower livers patients at risk developing HCC, and has been proposed to be a tumor-susceptibility gene liver cancer. The identification several children with disease as having mutations further suggests that this plays an important role function. In current study we studied...
The neuropathological confirmation of amyloid-β (Aβ) plaques and tau neurofibrillary tangles (NFT) remains the gold standard for a definitive diagnosis Alzheimer's disease (AD). Nowadays, in vivo AD is greatly aided by both cerebrospinal fluid (CSF) positron emission tomography (PET) biomarkers. Although highly accurate, their broad implementation restricted high cost, limited accessibility invasiveness. We recently developed high-performance, ultrasensitive immunoassay quantification...
Abstract Introduction This study investigated the diagnostic and disease‐monitoring potential of plasma biomarkers in mild cognitive impairment (MCI) Alzheimer's disease (AD) dementia cognitively unimpaired (CU) individuals. Methods Plasma was analyzed using Simoa assays from 99 CU, 107 MCI, 103 AD participants. Results Phosphorylated‐tau181 (P‐tau181), neurofilament light, amyloid‐β (Aβ42/40), Total‐tau Glial fibrillary acidic protein were altered but P‐tau181 significantly outperformed all...
Abstract Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer’s disease are needed to facilitate the initial screening process of participants disease-modifying trials. Previous biofluid data suggest that phosphorylated tau231 (p-tau231) could indicate incipient Aβ pathology, but a comprehensive comparison with other putative blood is lacking. In ALFA+ cohort, all tested plasma (p-tau181, p-tau217, p-tau231, GFAP, NfL and Aβ42/40) were significantly changed...
Importance Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease (AD) pathology, with p-tau217 considered to have the most utility. However, availability of tests research and clinical use has been limited. Expanding access this highly accurate AD crucial wider evaluation implementation tests. Objective To determine utility novel commercially available immunoassay plasma detect pathology evaluate reference ranges abnormal amyloid β (Aβ) longitudinal change across 3...
Plasma phosphorylated tau at threonine 181 (p-tau181) has been proposed as an easily accessible biomarker for the detection of Alzheimer disease (AD) pathology, but its ability to monitor progression in AD remains unclear.To study potential longitudinal plasma p-tau181 measures assessing neurodegeneration and cognitive decline comparison neurofilament light chain (NfL), a disease-nonspecific marker neuronal injury.This cohort included data from Alzheimer's Disease Neuroimaging Initiative...
Abstract Tau phosphorylated at threonine 181 (p-tau181) measured in blood plasma has recently been proposed as an accessible, scalable, and highly specific biomarker for Alzheimer’s disease. Longitudinal studies, however, investigating the temporal dynamics of this novel are lacking. It is therefore unclear when disease process p-tau181 increases above physiological levels how it relates to spatiotemporal progression characteristic pathologies. We aimed establish natural time course across...
Abstract Gold-standard diagnosis of Alzheimer’s disease (AD) relies on histopathological staging systems. Using the topographical information from [ 18 F]MK6240 tau positron-emission tomography (PET), we applied Braak system to 324 living individuals. We used PET-based stage model trajectories amyloid-β, phosphorylated (pTau) in cerebrospinal fluid (pTau 181 , pTau 217 231 and 235 ) plasma ), neurodegeneration cognitive symptoms. identified nonlinear AD biomarker corresponding spatial extent...
Plasma biomarkers related to amyloid, tau, and neurodegeneration (ATN) show great promise for identifying these pathological features of Alzheimer's Disease (AD) as shown by recent clinical studies selected autopsy studies. We have evaluated ATN plasma in a series 312 well-characterized longitudinally followed research subjects with available within 5 years or less before examined relation spectrum AD pathologies. Aβ42, Aβ40, total Tau, P-tau181, P-tau231 neurofilament light (NfL) were...
Importance The recent proliferation of phosphorylated tau (p-tau) biomarkers has raised questions about their preferential association with the hallmark pathologies Alzheimer disease (AD): amyloid-β plaques and neurofibrillary tangles. Objective To determine whether cerebrospinal fluid (CSF) plasma p-tau preferentially reflect cerebral β-amyloidosis or tangle aggregation measured positron emission tomography (PET). Design, Setting, Participants This was a cross-sectional study 2...
Abstract Introduction Direct comparisons of the main blood phosphorylated tau immunoassays in memory clinic populations are needed to understand possible differences. Methods In BIODEGMAR study, 197 participants presenting with cognitive complaints were classified into an Alzheimer's disease (AD) or a non‐AD cerebrospinal fluid (CSF) profile group, according their amyloid beta 42/ (Aβ42/p‐tau) ratio. We performed head‐to‐head comparison nine plasma and CSF determined accuracy discriminate...
In pre-clinical Alzheimer’s disease, cerebral amyloid-β (Aβ) deposition precedes symptoms; Aβ-targeted therapies may have maximum benefits at this stage. Existing Aβ status measurement techniques, including amyloid PET and CSF testing, are difficult to upscale. We therefore compared the concordance of three different blood-based techniques (liquid chromatography-mass spectrometry (LC¬-MS) measures plasma Aβ, single molecule array (Simoa) phospho-tau181 (p-tau181)) with PET-positivity in...
Antiamyloid immunotherapies against Alzheimer disease (AD) are emerging. Scalable, cost-effective tools will be needed to identify amyloid β (Aβ)-positive patients without an advanced stage of tau pathology who most likely benefit from these therapies. Blood-based biomarkers might reduce the need use cerebrospinal fluid (CSF) or positron emission tomography (PET) for this.
Abstract Blood phosphorylated tau (p-tau) biomarkers, at differing sites, demonstrate high accuracy to detect Alzheimerʼs disease (AD). However, knowledge on the optimal marker for identification across AD continuum and link pathology is limited. This partly due heterogeneity in analytical methods. In this study, we employed an immunoprecipitation mass spectrometry method simultaneously quantify six (p-tau181, p-tau199, p-tau202, p-tau205, p-tau217 p-tau231) two non-phosphorylated plasma...
Abstract BACKGROUND We aimed to evaluate the precision of Alzheimer's disease (AD) and neurodegeneration biomarker measurements from venous dried plasma spots (DPS v enous ) for diagnosis monitoring neurodegenerative diseases in remote settings. METHODS In a discovery ( n = 154) validation cohort 115), glial fibrillary acidic protein (GFAP); neurofilament light (NfL); amyloid beta (Aβ) 40, Aβ42; phosphorylated tau (p‐tau181 p‐tau217) were measured paired DPS ethylenediaminetetraacetic acid...
Abstract Background Novel phosphorylated-tau (p-tau) blood biomarkers (e.g., p-tau181, p-tau217 or p-tau231), are highly specific for Alzheimer’s disease (AD), and can track amyloid-β (Aβ) tau pathology. However, because these strongly associated with the emergence of Aβ pathology, it is difficult to determine contribution insoluble aggregates plasma p-tau signal in blood. Therefore, there remains a need biomarker capable specifically tracking accumulation brain. Methods NTA novel...
Abstract Post-mortem staging of Alzheimer’s disease (AD) neurofibrillary pathology is commonly performed by immunohistochemistry using AT8 antibody for phosphorylated tau (p-tau) at positions 202/205. Thus, quantification p-tau205 and p-tau202 in cerebrospinal fluid (CSF) should be more reflective tangles AD than other p-tau epitopes. We developed two novel Simoa immunoassays CSF measured these phosphorylations three independent cohorts encompassing the continuum , non-AD cases cognitively...
Objective To assess the diagnostic and prognostic value of serum neurofilament light (NfL) phospho-Tau 181 (p-Tau ) in a large cohort patients with frontotemporal lobar degeneration (FTLD). Methods In this retrospective study, performed on 417 participants, we analysed NfL p-Tau concentrations an ultrasensitive single molecule array (Simoa) approach. We assessed values biomarkers differential diagnosis between FTLD, Alzheimer’s disease (AD) healthy ageing; their role as markers severity...
Phosphorylated tau (p-tau) in cerebrospinal fluid (CSF) is an established Alzheimer's disease (AD) biomarker. Novel immunoassays targeting N-terminal and mid-region p-tau181 p-tau217 fragments are available, but head-to-head comparison clinical settings lacking.N-terminal-directed (N-p-tau217), N-terminal-directed (N-p-tau181), standard (Mid-p-tau181) biomarkers CSF were evaluated three cohorts (n = 503) to assess diagnostic performance, concordance, associations with amyloid beta (Aβ).CSF...